MedTrace Logo

MHNA-001 for Young Adults With IBS

NCT05333926 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2023-03-14

No results posted yet for this study

Summary

The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ IBS together with care as usual in approximately 100 young adults with Irritable Bowel Syndrome.

Conditions

  • Irritable Bowel Syndrome

Interventions

DEVICE

MHNA-001

3-month digital therapy program designed to reduce the severity of IBS symptoms

Sponsors & Collaborators

  • Mahana Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-12-22
Completion
2022-12-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05333926 on ClinicalTrials.gov